The 2026 Annual Meeting of the American Association for Cancer Research (AACR) concluded in San Diego under the theme "Precision · Partnership · Purpose." Key areas of focus included bispecific antibody--drug conjugates (ADCs), renewed development of established targets, and broad-spectrum targeted therapies.
AntibodySystem participated in AACR 2026, connecting with academic and industry teams to discuss practical challenges in translational research and to present reagents designed for reproducibility, specificity, and consistent performance across studies.
Throughout the meeting, our booth hosted researchers and drug discovery teams from North America, Europe, and Asia. Conversations centered on experimental design, assay selection, and data reproducibility across applications such as immuno-oncology, cell therapy, and biomarker analysis.
Reagents Aligned to Current Research Workflows
Founded in 2019, AntibodySystem develops and manufactures proteins, antibodies, and immunoassays supporting discovery through preclinical research. Our products are used across oncology, immunology, virology, and neuroscience, with an emphasis on lot-to-lot consistency and application performance.
- In Vivo Antibodies Validated for in vitro and in vivo activity to support mechanism-of-action studies. Applications: combination therapy evaluation, cytotoxicity assays, target validation.
- Flow Cytometry Antibodies Optimized for low background and multicolor panel compatibility. Applications: tumor microenvironment profiling, CAR-T phenotyping, immune monitoring.
- Drug Target Proteins High-purity proteins with controlled expression systems and consistent quality. Applications: binding assays, pathway studies, assay development, drug screening.
- PK / ADA ELISA Kits Designed for sensitivity, reproducibility, and streamlined workflows. Applications: cytokine quantification, biomarker screening, pharmacokinetic studies.
Supporting Ongoing Advances in Oncology
AACR continues to reflect the pace of innovation in cancer research. AntibodySystem remains focused on expanding target coverage and improving reagent performance to support emerging areas including bispecific ADCs, multi-target strategies, and combination immunotherapies.
Acknowledgments
We thank the researchers and partners who met with us during AACR 2026. Your feedback directly informs how we refine our products and support evolving research needs.
We look forward to continued collaboration with the global research community.
